

Clinical Services

Platform Technology	Name	Description	Specimen Requirements	Limit of Detection	Expected TAT	Reimbursement Codes**
PCR	LeukoStrat® CDx <i>FLT3</i> Mutation Assay*	FDA-approved assay predictive of RYDAPT®, XOSPATA® or VANFLYTA® efficacy	At least 1 mL of Peripheral Blood or 0.25 mL Bone Marrow in EDTA or Sodium Heparin	9%	2-3 Days	81245, 81246, 0023U
	<i>NPM1</i> Mutation Assay*	Qualitative assay for <i>NPM1</i> Mutations	At least 1 mL of Peripheral Blood or 0.25 mL Bone Marrow in EDTA or Sodium Heparin or at least 250 ng of isolated DNA	5%	1-3 Days	81310
dPCR	<i>KMT2A</i> MRD Assay	Measurable Residual Disease assay for <i>KMT2A</i> rearrangements	At least 1 mL of Peripheral Blood or 0.25 mL Bone Marrow in EDTA or 7.5 µg isolated RNA	0.005%	7-10 Days	n/a
NGS	<i>FLT3</i> ITD MRD Assay*	Measurable Residual Disease assay for <i>FLT3</i> ITD mutations	At least 1 mL of Peripheral Blood or 0.25 mL Bone Marrow in EDTA or 1 µg isolated DNA	0.005%	7-10 Days	0046U
	<i>NPM1</i> MRD Assay*	Measurable Residual Disease assay for <i>NPM1</i> mutations	At least 1 mL of Peripheral Blood or 0.25 mL Bone Marrow in EDTA or 1 µg isolated DNA	0.005%	7-10 Days	0049U
Gene Panel	MyAML®^	AML panel for 194 genes. Tests SNVs and structural variants	At least 3 mL of Peripheral Blood or 1 mL Bone Marrow in EDTA or Sodium Heparin or 1 µg isolated DNA	5%	14-21 Days	n/a
	MyMRD®^	Hotspot panel of 23 genes. Targets SNVs and indels in 21 genes plus 5 structural variant breakpoints	At least 3 mL of Peripheral Blood or 1 mL Bone Marrow in EDTA or Sodium Heparin or 1 µg isolated DNA	0.5%	14-21 Days	n/a
Multiparametric Flow Cytometry	Hematolymphoid Screening Panel	10-color flow panel with 29 biomarkers	At least 2 mL of Peripheral Blood or Bone Marrow in EDTA or Sodium Heparin	0.5-1.0% for most abnormalities	1-2 Days	88184, 88185, 88189
	CLL MRD Assay	11-color flow panel with 12 biomarkers	At least 2 mL of Peripheral Blood or Bone Marrow in EDTA or Sodium Heparin	0.005% - 0.002%	1-2 Days	88184, 88185, 88187
	AML MRD Assay	12-color flow panel with 21 biomarkers	At least 2 mL of Peripheral Blood or Bone Marrow in EDTA or Sodium Heparin	0.01%	1-2 Days	88184, 88185, 88189

* NYS Approved | Not all services are offered at all locations. Services in China are offered to support drug discovery and development. Inquire for availability.

** Reimbursement codes vary by country.

^ Research Use Only. Not intended for diagnostic purposes.